Morgan Stanley issued a bullish tactical view on Juzi Bio (http://2367.HK), believing that the probability of its stock price rising in the next 30 days is as high as 70%-80%. The key factor is that the current stock price has not positively reacted to its strong sales in the second quarter and the launch of its first recombinant collagen injection, and the valuation is undervalued. Sales in the first half of the year are expected to grow by about 20% quarter-on-quarter. The target price is set at HKD 43, while the current stock price is only HKD 27.04, corresponding to a 12 times price-to-earnings ratio for the next 12 months and a dividend yield of 4-5%. Concerns about the overall tightening of regulation and intensified competition in the medical aesthetics industry may cause the market to overlook Juzi Bio's strong product cycle and the upcoming significant catalysts.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。